These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36211392)

  • 1. Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment.
    Huang J
    Front Immunol; 2022; 13():1010946. PubMed ID: 36211392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.
    Chandra A; Valkimadi PE; Pagano G; Cousins O; Dervenoulas G; Politis M;
    Hum Brain Mapp; 2019 Dec; 40(18):5424-5442. PubMed ID: 31520513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
    Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory human PET study of the effectiveness of (11)C-ketoprofen methyl ester, a potential biomarker of neuroinflammatory processes in Alzheimer's disease.
    Ohnishi A; Senda M; Yamane T; Mikami T; Nishida H; Nishio T; Akamatsu G; Ikari Y; Kimoto S; Aita K; Sasaki M; Shinkawa H; Yamamoto Y; Shukuri M; Mawatari A; Doi H; Watanabe Y; Onoe H
    Nucl Med Biol; 2016 Jul; 43(7):438-44. PubMed ID: 27183464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease.
    Janssen B; Mach RH
    Prog Mol Biol Transl Sci; 2019; 165():371-399. PubMed ID: 31481170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
    Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
    J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo PET imaging of neuroinflammation in Alzheimer's disease.
    Lagarde J; Sarazin M; Bottlaender M
    J Neural Transm (Vienna); 2018 May; 125(5):847-867. PubMed ID: 28516240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease.
    Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
    Med Image Anal; 2018 May; 46():26-34. PubMed ID: 29502031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of positron emission tomography imaging in understanding Alzheimer's disease.
    Barthel H; Seibyl J; Sabri O
    Expert Rev Neurother; 2015 Apr; 15(4):395-406. PubMed ID: 25752209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation in mild cognitive impairment and Alzheimer's disease: A meta-analysis.
    Bradburn S; Murgatroyd C; Ray N
    Ageing Res Rev; 2019 Mar; 50():1-8. PubMed ID: 30610927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment.
    Knezevic D; Mizrahi R
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt B):123-131. PubMed ID: 28533150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach.
    Rodriguez-Vieitez E; Nordberg A
    Methods Mol Biol; 2018; 1750():231-251. PubMed ID: 29512077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging of Neuroinflammation in Alzheimer's Disease and Mild Cognitive Impairment.
    Kim J; Kim YK
    Adv Exp Med Biol; 2023; 1411():301-326. PubMed ID: 36949316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.